Category: Press Release - Page 89 - Psychedelic Alpha

Read more about the article MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

Post published:November 18, 2021
Post category:Press Release

Read more about the article Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

Post published:November 18, 2021
Post category:Press Release

Read more about the article Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

Post published:November 18, 2021
Post category:Press Release

Read more about the article CaaMTech Teams Up With University of Wyoming to Study Psychedelics as Treatments for Addiction

CaaMTech Teams Up With University of Wyoming to Study Psychedelics as Treatments for Addiction

Post published:November 16, 2021
Post category:Press Release

Read more about the article MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

Post published:November 16, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Post published:November 16, 2021
Post category:Press Release

Read more about the article MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures

Post published:November 16, 2021
Post category:Press Release

Read more about the article MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline

MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline

Post published:November 15, 2021
Post category:Press Release

Read more about the article atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

Post published:November 15, 2021
Post category:Press Release

Read more about the article Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

Post published:November 15, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.